Startseite
Impressum
Datenschutz
 
 
  SPOT ON
 

Orphan drug pirfenidone (ESBRIET): benefit legally enacted

Summary of product characteristics - updated at a snail´s pace

 
  NEW ON THE MARKET
 

Botulinum toxin type A (BOTOX) against chronic migraine

 
  a-t READER'S QUESTIONS AND COMMENTS
 

Discount contracts: boon or bane?

Tamoxifen and CYP 2D6 testing: what´s new?

 
  IN BRIEF
 

Recourse due to fictitiously approved drugs

Pancreatitis - sitagliptin (JANUVIA, XELEVIA) safety study is overdue

Confirmed - ADHD more often diagnosed in the youngest children of a class

Association Voluntary Self-Regulation for the Pharmaceutical Industry (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.) on "ordering" of samples via the courier

 
  CURRENT ADR NETWORK REPORT

Fatal rhabdomyolysis following isotretionin

 
  SIDE EFFECTS
 

Severe allergy to mould fungus homeopathics

Severe hypersensitivity reaction against gout medication febuxostat (ADENURIC)

New contraindication for strontium ranelate (PROTELOS)

 
  e a-t IN INTERNET
 

Fictitiously approved drugs: information supplementing the in brief story

 

© arznei-telegramm 4/2012